197 related articles for article (PubMed ID: 17660022)
1. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
Izzedine H; Rixe O; Billemont B; Baumelou A; Deray G
Am J Kidney Dis; 2007 Aug; 50(2):203-18. PubMed ID: 17660022
[TBL] [Abstract][Full Text] [Related]
2. Renal effects of anti-angiogenesis therapy: update for the internist.
Gurevich F; Perazella MA
Am J Med; 2009 Apr; 122(4):322-8. PubMed ID: 19332223
[TBL] [Abstract][Full Text] [Related]
3. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
4. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
Izzedine H; Massard C; Spano JP; Goldwasser F; Khayat D; Soria JC
Eur J Cancer; 2010 Jan; 46(2):439-48. PubMed ID: 20006922
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
Kappers MH; van Esch JH; Sleijfer S; Danser AH; van den Meiracker AH
J Hypertens; 2009 Dec; 27(12):2297-309. PubMed ID: 19680138
[TBL] [Abstract][Full Text] [Related]
6. [Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
Izzedine H
Bull Cancer; 2007 Nov; 94(11):981-6. PubMed ID: 18055316
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
Keedy VL; Sandler AB
Cancer Sci; 2007 Dec; 98(12):1825-30. PubMed ID: 17892508
[TBL] [Abstract][Full Text] [Related]
9. Electrolyte disorders related to EGFR-targeting drugs.
Izzedine H; Bahleda R; Khayat D; Massard C; Magné N; Spano JP; Soria JC
Crit Rev Oncol Hematol; 2010 Mar; 73(3):213-9. PubMed ID: 19403315
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic-induced hypertension: the molecular basis of signaling network.
Nagai A; Sado T; Naruse K; Noguchi T; Haruta S; Yoshida S; Tanase Y; Tsunemi T; Kobayashi H
Gynecol Obstet Invest; 2012; 73(2):89-98. PubMed ID: 22222493
[TBL] [Abstract][Full Text] [Related]
11. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
Vigneau C; Rioux-Leclercq N
Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
[TBL] [Abstract][Full Text] [Related]
12. [Anticancer drugs under pressure].
Ben Aïssa A; George AC; El M'Rabet FZ; Mach N; Dietrich PY; Pechère-Bertschi A
Rev Med Suisse; 2011 Sep; 7(308):1761-6. PubMed ID: 21954818
[TBL] [Abstract][Full Text] [Related]
13. Functional symbiosis between endothelium and epithelial cells in glomeruli.
Hirschberg R; Wang S; Mitu GM
Cell Tissue Res; 2008 Feb; 331(2):485-93. PubMed ID: 17999087
[TBL] [Abstract][Full Text] [Related]
14. Global upregulation of gene expression associated with renal dysfunction in DOCA-salt-induced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor: a microarray analysis.
Benter IF; Canatan H; Benboubetra M; Yousif MH; Akhtar S
Vascul Pharmacol; 2009; 51(2-3):101-9. PubMed ID: 19410658
[TBL] [Abstract][Full Text] [Related]
15. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
Cosmai L; Gallieni M; Liguigli W; Porta C
J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
[TBL] [Abstract][Full Text] [Related]
16. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
van Heeckeren WJ; Ortiz J; Cooney MM; Remick SC
J Clin Oncol; 2007 Jul; 25(21):2993-5. PubMed ID: 17634476
[No Abstract] [Full Text] [Related]
17. Combination targeted therapy in advanced renal cell carcinoma.
Sosman J; Puzanov I
Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
[TBL] [Abstract][Full Text] [Related]
18. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
Izzedine H; Mangier M; Ory V; Zhang SY; Sendeyo K; Bouachi K; Audard V; Péchoux C; Soria JC; Massard C; Bahleda R; Bourry E; Khayat D; Baumelou A; Lang P; Ollero M; Pawlak A; Sahali D
Kidney Int; 2014 Feb; 85(2):457-70. PubMed ID: 24067439
[TBL] [Abstract][Full Text] [Related]
19. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.
Eremina V; Quaggin SE
Semin Nephrol; 2010 Nov; 30(6):582-90. PubMed ID: 21146123
[TBL] [Abstract][Full Text] [Related]
20. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
